The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread
- PMID: 20013531
- DOI: 10.1055/s-0029-1242718
The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread
Abstract
The relationship between hemostasis and malignancy is well recognized, with both elements interacting in a "vicious cycle" where cancers overexpress procoagulants and thrombin, which in turn promote both prothrombotic potential and tumor growth, invasion, and spread. Indeed, venous thromboembolism, particularly idiopathic venous thrombosis, occurs frequently as a paraneoplastic phenomenon, and in turn several components of primary and secondary hemostasis (namely platelets, tissue factor, and thrombin) play an important role in primary tumor growth and metastasization. Despite the many and various mechanisms involved in this multifaceted relationship, anticoagulants might represent an attractive anticancer therapy, in that current research supports the hypothesis that such drugs may offer a better control of cancer progression. The main biological and clinical evidence on the relationship between cancer and hemostasis are briefly summarized in this review, as is the potential benefits of anticoagulant therapy in this setting.
(c) Thieme Medical Publishers.
Similar articles
-
The role of procoagulants and anticoagulants in the development of venous thromboembolism.Thromb Res. 2009;123 Suppl 4:S41-5. doi: 10.1016/S0049-3848(09)70142-2. Thromb Res. 2009. PMID: 19303503 Review.
-
Microparticles and cancer thrombosis in animal models.Thromb Res. 2016 Apr;140 Suppl 1:S21-6. doi: 10.1016/S0049-3848(16)30094-9. Thromb Res. 2016. PMID: 27067974 Review.
-
Development in anticoagulant therapy.Crit Rev Oncol Hematol. 2008 May;66(2):145-54. doi: 10.1016/j.critrevonc.2007.09.009. Epub 2007 Nov 26. Crit Rev Oncol Hematol. 2008. PMID: 18032061 Review.
-
Rethinking the approach to thrombosis in patients with cancer.Vasc Med. 2020 Jun;25(3):208-209. doi: 10.1177/1358863X19886354. Epub 2019 Nov 13. Vasc Med. 2020. PMID: 31718489 No abstract available.
-
Anticoagulants versus cancer.Thromb Res. 2016 Apr;140 Suppl 1:S148-53. doi: 10.1016/S0049-3848(16)30114-1. Thromb Res. 2016. PMID: 27067969 Review.
Cited by
-
Quantitative estimation of Serum Fibrinogen Degradation Product levels in Oral Premalignant and Malignant lesions.J Int Oral Health. 2013 Oct;5(5):65-72. Epub 2013 Oct 26. J Int Oral Health. 2013. PMID: 24324307 Free PMC article.
-
A Machine Learning Method to Trace Cancer Primary Lesion Using Microarray-Based Gene Expression Data.Front Oncol. 2022 Apr 21;12:832567. doi: 10.3389/fonc.2022.832567. eCollection 2022. Front Oncol. 2022. PMID: 35530331 Free PMC article.
-
Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis.Clin Appl Thromb Hemost. 2018 Mar;24(2):226-234. doi: 10.1177/1076029617696581. Epub 2017 Mar 14. Clin Appl Thromb Hemost. 2018. PMID: 28288527 Free PMC article.
-
Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.Eur J Clin Pharmacol. 2022 Oct;78(10):1555-1565. doi: 10.1007/s00228-022-03365-4. Epub 2022 Jul 23. Eur J Clin Pharmacol. 2022. PMID: 35871241 Free PMC article. Review.
-
The evolution of anticoagulant therapy.Blood Transfus. 2016 Mar;14(2):175-84. doi: 10.2450/2015.0096-15. Epub 2015 Dec 16. Blood Transfus. 2016. PMID: 26710352 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical